Global /Pakistan /Healthcare /Drug Manufacturers - General /CPHL

Citi Pharma Ltd.

CPHL

• PSX: CPHL • Delayed

78.06PKR -1.2%

0.2806 USD

As of 13 June 2026, Citi Pharma Ltd. has a market cap of $64.12M USD, ranking #28746 globally and #129 in Pakistan. It ranks #2608 in the Healthcare sector, and #926 in the Drug Manufacturers - General industry.

Global Rank

28746

Country Rank

129

Sector Rank

2608

Industry Rank

926

Key Stats

Market Cap

$64.12MUSD

17.83B PKR

Enterprise Value

$73.28MUSD

20.38B PKR

Revenue (TTM)

$50.69MUSD

14.1B PKR

EBITDA (TTM)

$8.11MUSD

2.26B PKR

Net Income (TTM)

$3.74MUSD

1.04B PKR

EBITDA Margin

16%

Profit Margin

7.4%

PE Ratio

17.2

Forward PE

18.6

PS Ratio

1.3

PB Ratio

1.7

EV/EBITDA

8.9

Company Profile

Country (HQ)

Pakistan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Rizwan Ahmad open_in_new

Employees

531

Founded

2012

Website

citipharma.com.pk open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.2%	-8.3%	7.7%	-8.8%	-6%	-6.6%	-6.1%	194%	158%

News

Markets

Exchange	Ticker	Price	Quotes
Pakistan Stock Exchange (PSX) MIC: XKAR PRIMARY	CPHL Citi Pharma Ltd Ordinary Shares ISIN: PK0126201018 Shares Out.: Shares Outstanding: 228.461M¹ Shares Float: 137.467M² TV: TradingView: PSX: CPHL SA: Stock Analysis: PSX: CPHL YF: Yahoo Finance: CPHL.KA GF: Google Finance: PSX: CPHL BA: Barron's: CPHL MS: Morningstar: XKAR: CPHL	78.06 PKR	TV: TradingView: PSX: CPHL SA: Stock Analysis: PSX: CPHL YF: Yahoo Finance: CPHL.KA GF: Google Finance: PSX: CPHL BA: Barron's: CPHL MS: Morningstar: XKAR: CPHL

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Citi Pharma Ltd.

Citi Pharma Limited engages in the manufacture and sale of pharmaceutical, medical chemical, and botanical products in Pakistan. Its product portfolio includes capsules, tablet, syrup drops, ointment, sachet, and formulation. Citi Pharma Limited was incorporated in 2012 and is headquartered in Lahore, Pakistan.

Similar Companies

Industry: Drug Manufacturers - General (Pakistan)

Name	Market Cap (USD) diff.	PE	Country
GlaxoSmithKline Pakistan Ltd. PSX: GLAXO	$399.79M 111.2B PKR 524%	11.1	Pakistan
Abbott Laboratories (Pakistan) Ltd. PSX: ABOT	$319.38M 88.83B PKR 398%	10.7	Pakistan
Haleon Pakistan Ltd. PSX: HALEON	$313.86M 87.29B PKR 389%	13.7	Pakistan
AGP Ltd. PSX: AGP	$182.93M 50.88B PKR 185%	13.6	Pakistan
The Searle Company Ltd. PSX: SEARL	$182.62M 50.79B PKR 185%	27.9	Pakistan
Highnoon Laboratories Ltd. PSX: HINOON	$179.1M 49.81B PKR 179%	12.1	Pakistan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 853K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 562K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 501K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 450K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 428K%	20.5	Switzerland

chevron_leftBack